Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Fuji
Merck
Harvard Business School
Chinese Patent Office
US Army

Generated: June 17, 2019

DrugPatentWatch Database Preview

Deferasirox - Generic Drug Details

« Back to Dashboard

What are the generic sources for deferasirox and what is the scope of deferasirox freedom to operate?

Deferasirox is the generic ingredient in four branded drugs marketed by Novartis Pharms Corp, Actavis Elizabeth, and Novartis, and is included in four NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Deferasirox has one hundred and one patent family members in fifty countries.

There are twenty drug master file entries for deferasirox. Two suppliers are listed for this compound.

US Patents and Regulatory Information for deferasirox

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Elizabeth DEFERASIROX deferasirox TABLET, FOR SUSPENSION;ORAL 203560-003 Jan 26, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-003 Mar 30, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Actavis Elizabeth DEFERASIROX deferasirox TABLET, FOR SUSPENSION;ORAL 203560-002 Jan 26, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-002 Mar 30, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for deferasirox

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXJADE deferasirox TABLET, FOR SUSPENSION;ORAL 021882-001 Nov 2, 2005 ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-002 Mar 30, 2015 ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-002 Mar 30, 2015 ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp JADENU SPRINKLE deferasirox GRANULE;ORAL 207968-001 May 18, 2017 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for deferasirox

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0914118 C00914118/01 Switzerland ➤ Sign Up PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005
0914118 SPC 035/2006 Ireland ➤ Sign Up SPC 035/2006: 20070528, EXPIRES: 20210827
0914118 290 Finland ➤ Sign Up
0914118 PA2007001 Lithuania ➤ Sign Up PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Julphar
Covington
US Army
Argus Health
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.